NewsSynapse Electroceutical Ltd enters into distribution agreement with H&R Healthcare Ltd

Synapse Electroceutical Ltd enters into distribution agreement with H&R Healthcare Ltd

Products

Synapse Electroceutical Ltd enters into distribution agreement with H&R Healthcare LtdSynapse Electroceutical Ltd are pleased to announce a new partnership with H&R Healthcare, the UK distributors of highest quality medical devices sourced from leading manufacturer around the world, for the distribution of Accel-Heal®, a Synapse Externally Applied Electroceutical (EAE) technology.

Commenting on the agreement John Gildersleeve, CEO of Synapse said: “We are delighted to be working in partnership with H&R Healthcare enriching their wound care portfolio with our EAE Accel-Heal®. The H&R team with their expertise in the distribution of highly effective and innovative wound care products are the perfect partner for Accel-Heal®”
Accel-Heal® is an EAE for the treatment of complex wounds and is the only EAE proven to expedite effective healing by changing physiological processes implicated in wound complexity. Accel-Heal®, uses micro-currents to support tissue repair by interacting with biological processes that have become static within the wound, targeting a key underlying cause of why wounds do not heal.
Mike Hoskins, MD of H&R Healthcare stated “We are delighted to be able to bring the benefits of Accel-Heal® to both patients and carers. Accel-Heal® is a genuine breakthrough technology for the treatment of leg ulcers, combining outstanding clinical outcomes with excellent value for money to the NHS”
Accel-Heal® will be listed on drug tariff and available for clinical prescribing from 1 October 2015. It is a 12 day treatment course consisting of six, pre-programmed, battery powered, 48 hour single use units, applied consecutively and is the world’s first disposable system.